Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia

Jonathan R. Brody, Agnes Witkiewicz, Timothy K. Williams, Shrihari S. Kadkol, Joseph Cozzitorto, Brandice Durkan, Gary R. Pasternack, Charles J. Yeo

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Nuclear phosphoprotein 32 (pp32) inhibits K-ras induced transformation in experimental models. pp32 mRNA expression correlates with differentiation status in breast and prostate cancers. In this study, we evaluated pp32 protein expression in relation to the differentiation status of pancreatic ductal adenocarcinomas and precursor lesions of the pancreatic cancers. pp32 expression showed strong nuclear staining in normal pancreatic acini and ducts. The intensity of this staining was maintained in pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasms with mild dysplasia, well-differentiated adenocarcinomas, and in a subset of moderately differentiated adenocarcinomas. pp32 staining was absent or reduced in poorly differentiated tumors and in intraductal papillary mucinous neoplasms with moderate dysplasia. We validated pp32 expression by a second technique, immunoblot analysis of lysates from resected pancreatic ductal adenocarcinomas and pancreatic cancer cell lines. The well-differentiated pancreatic cancer cell line HPAC expressed high amounts of pp32, as compared to the poorly differentiated pancreatic cancer cell lines MiaPaCa2, Pl19, and Pl21 cells. Artificial introduction of pp32 expression into a poorly differentiated cell line, MiaPaCa2, caused an increase in G1 arrest compared to control cells. On the basis of this study and previous functional work that shows pp32 can inhibit K-ras transformation, we propose that reduction in pp32 expression levels may be a critical event in the progression of pancreatic tumorigenesis in an aggressive subset of pancreatic ductal adenocarcinomas.

Original languageEnglish (US)
Pages (from-to)1238-1244
Number of pages7
JournalModern Pathology
Volume20
Issue number12
DOIs
StatePublished - Dec 14 2007

Fingerprint

Papillary Adenocarcinoma
Phosphoproteins
Neoplasms
Adenocarcinoma
Pancreatic Neoplasms
Cell Line
Staining and Labeling
Pancreatic Ducts
Prostatic Neoplasms
Carcinogenesis
Theoretical Models

Keywords

  • Intraductal papillary mucinous neoplasms
  • Pancreatic ductal adenocarcinoma
  • Poorly differentiated pancreatic adenocarcinomas
  • pp32 (ANP32A)
  • Protein expression
  • Tumor suppressor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia. / Brody, Jonathan R.; Witkiewicz, Agnes; Williams, Timothy K.; Kadkol, Shrihari S.; Cozzitorto, Joseph; Durkan, Brandice; Pasternack, Gary R.; Yeo, Charles J.

In: Modern Pathology, Vol. 20, No. 12, 14.12.2007, p. 1238-1244.

Research output: Contribution to journalArticle

Brody, Jonathan R. ; Witkiewicz, Agnes ; Williams, Timothy K. ; Kadkol, Shrihari S. ; Cozzitorto, Joseph ; Durkan, Brandice ; Pasternack, Gary R. ; Yeo, Charles J. / Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia. In: Modern Pathology. 2007 ; Vol. 20, No. 12. pp. 1238-1244.
@article{bc9c86d59766411f8c247e89d7392fdb,
title = "Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia",
abstract = "Nuclear phosphoprotein 32 (pp32) inhibits K-ras induced transformation in experimental models. pp32 mRNA expression correlates with differentiation status in breast and prostate cancers. In this study, we evaluated pp32 protein expression in relation to the differentiation status of pancreatic ductal adenocarcinomas and precursor lesions of the pancreatic cancers. pp32 expression showed strong nuclear staining in normal pancreatic acini and ducts. The intensity of this staining was maintained in pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasms with mild dysplasia, well-differentiated adenocarcinomas, and in a subset of moderately differentiated adenocarcinomas. pp32 staining was absent or reduced in poorly differentiated tumors and in intraductal papillary mucinous neoplasms with moderate dysplasia. We validated pp32 expression by a second technique, immunoblot analysis of lysates from resected pancreatic ductal adenocarcinomas and pancreatic cancer cell lines. The well-differentiated pancreatic cancer cell line HPAC expressed high amounts of pp32, as compared to the poorly differentiated pancreatic cancer cell lines MiaPaCa2, Pl19, and Pl21 cells. Artificial introduction of pp32 expression into a poorly differentiated cell line, MiaPaCa2, caused an increase in G1 arrest compared to control cells. On the basis of this study and previous functional work that shows pp32 can inhibit K-ras transformation, we propose that reduction in pp32 expression levels may be a critical event in the progression of pancreatic tumorigenesis in an aggressive subset of pancreatic ductal adenocarcinomas.",
keywords = "Intraductal papillary mucinous neoplasms, Pancreatic ductal adenocarcinoma, Poorly differentiated pancreatic adenocarcinomas, pp32 (ANP32A), Protein expression, Tumor suppressor",
author = "Brody, {Jonathan R.} and Agnes Witkiewicz and Williams, {Timothy K.} and Kadkol, {Shrihari S.} and Joseph Cozzitorto and Brandice Durkan and Pasternack, {Gary R.} and Yeo, {Charles J.}",
year = "2007",
month = "12",
day = "14",
doi = "10.1038/modpathol.3800974",
language = "English (US)",
volume = "20",
pages = "1238--1244",
journal = "Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia

AU - Brody, Jonathan R.

AU - Witkiewicz, Agnes

AU - Williams, Timothy K.

AU - Kadkol, Shrihari S.

AU - Cozzitorto, Joseph

AU - Durkan, Brandice

AU - Pasternack, Gary R.

AU - Yeo, Charles J.

PY - 2007/12/14

Y1 - 2007/12/14

N2 - Nuclear phosphoprotein 32 (pp32) inhibits K-ras induced transformation in experimental models. pp32 mRNA expression correlates with differentiation status in breast and prostate cancers. In this study, we evaluated pp32 protein expression in relation to the differentiation status of pancreatic ductal adenocarcinomas and precursor lesions of the pancreatic cancers. pp32 expression showed strong nuclear staining in normal pancreatic acini and ducts. The intensity of this staining was maintained in pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasms with mild dysplasia, well-differentiated adenocarcinomas, and in a subset of moderately differentiated adenocarcinomas. pp32 staining was absent or reduced in poorly differentiated tumors and in intraductal papillary mucinous neoplasms with moderate dysplasia. We validated pp32 expression by a second technique, immunoblot analysis of lysates from resected pancreatic ductal adenocarcinomas and pancreatic cancer cell lines. The well-differentiated pancreatic cancer cell line HPAC expressed high amounts of pp32, as compared to the poorly differentiated pancreatic cancer cell lines MiaPaCa2, Pl19, and Pl21 cells. Artificial introduction of pp32 expression into a poorly differentiated cell line, MiaPaCa2, caused an increase in G1 arrest compared to control cells. On the basis of this study and previous functional work that shows pp32 can inhibit K-ras transformation, we propose that reduction in pp32 expression levels may be a critical event in the progression of pancreatic tumorigenesis in an aggressive subset of pancreatic ductal adenocarcinomas.

AB - Nuclear phosphoprotein 32 (pp32) inhibits K-ras induced transformation in experimental models. pp32 mRNA expression correlates with differentiation status in breast and prostate cancers. In this study, we evaluated pp32 protein expression in relation to the differentiation status of pancreatic ductal adenocarcinomas and precursor lesions of the pancreatic cancers. pp32 expression showed strong nuclear staining in normal pancreatic acini and ducts. The intensity of this staining was maintained in pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasms with mild dysplasia, well-differentiated adenocarcinomas, and in a subset of moderately differentiated adenocarcinomas. pp32 staining was absent or reduced in poorly differentiated tumors and in intraductal papillary mucinous neoplasms with moderate dysplasia. We validated pp32 expression by a second technique, immunoblot analysis of lysates from resected pancreatic ductal adenocarcinomas and pancreatic cancer cell lines. The well-differentiated pancreatic cancer cell line HPAC expressed high amounts of pp32, as compared to the poorly differentiated pancreatic cancer cell lines MiaPaCa2, Pl19, and Pl21 cells. Artificial introduction of pp32 expression into a poorly differentiated cell line, MiaPaCa2, caused an increase in G1 arrest compared to control cells. On the basis of this study and previous functional work that shows pp32 can inhibit K-ras transformation, we propose that reduction in pp32 expression levels may be a critical event in the progression of pancreatic tumorigenesis in an aggressive subset of pancreatic ductal adenocarcinomas.

KW - Intraductal papillary mucinous neoplasms

KW - Pancreatic ductal adenocarcinoma

KW - Poorly differentiated pancreatic adenocarcinomas

KW - pp32 (ANP32A)

KW - Protein expression

KW - Tumor suppressor

UR - http://www.scopus.com/inward/record.url?scp=36249024805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36249024805&partnerID=8YFLogxK

U2 - 10.1038/modpathol.3800974

DO - 10.1038/modpathol.3800974

M3 - Article

C2 - 17906614

AN - SCOPUS:36249024805

VL - 20

SP - 1238

EP - 1244

JO - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

JF - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

SN - 0893-3952

IS - 12

ER -